乳腺癌干细胞分泌MIF以调解瘤代谢重编程,驱动免疫逃避
Linlin Yan1,2, Mingming Wu1,2, Tianyu Wang1,2
1Division of Life Sciences and Medicine, Department of Oncology, The First Affiliated Hospital of USTC, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, University of Science and Technology of China, Hefei, Anhui, China.
Cancer research
|February 9, 2024
概括
来自乳腺癌干细胞的巨细胞迁移抑制因子 (MIF) 驱动代谢重编程,并创造一种免疫抑制瘤环境. 向MIF可能会提高乳腺癌免疫疗法的有效性.
科学领域:
- 在瘤学瘤学.
- 癌症新陈代谢 癌症新陈代谢
- 免疫学 免疫学 免疫学
背景情况:
- 癌细胞重新编程能量新陈代谢以进行进展和免疫逃避.
- 了解代谢重编程机制是开发新型癌症疗法的关键.
研究的目的:
- 研究乳腺癌干细胞 (BCSC) 机密体在代谢重编程中的作用.
- 确定介导这些代谢变化的关键因素及其对瘤微环境和免疫疗法的影响.
主要方法:
- 来自缺氧和乳腺癌干细胞 (BCSC) 的秘密体的分析.
- 查BCSC的分泌基因,以确定增强糖解的因素.
- 研究MIF在通过c-MYC和WNT/β-catenin信号调节中的机械作用.
- 在体内评估MIF向瘤生长,转移和免疫细胞透的影响.
- 评估MIF向与免疫检查点封锁相结合的有效性.
主要成果:
- BCSC的分泌物重新编程了正常的乳腺癌细胞代谢,特别是糖解.
- 巨细胞迁移抑制因子 (MIF) 被确定为糖解的关键驱动因素.
- MIF激活了WNT/β-catenin信号,导致c-MYC介导的阿尔多酶C的上调.
- 向MIF降低了糖解,损害了瘤生长和转移,并调节了瘤免疫微环境.
- 通过增加CD8+T细胞和M1巨细胞,同时减少Tregs和MDSCs,MIF消耗增强了抗瘤免疫力.
- 在三阴性乳腺癌模型中,MIF抑制提高了免疫检查点阻塞的有效性.
结论:
- 由BCSCs分泌的MIF促进了代谢重编程和乳腺癌中的免疫抑制.
- 向MIF代表了一个有前途的治疗策略,以克服代谢适应和乳腺癌中的免疫逃避.
- 抑制MIF可以提高当前免疫疗法的有效性.
相关概念视频
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Mesenchymal Stem Cells
4.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


